Axa
ESPR

Axa’s Esperion Therapeutics ESPR Stock Holding History

Axa’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-782,085
Closed -$1.24M – 1108
2023
Q1 		$1.24M Sell
782,085
-6,281
-0.8% -$32.4K ﹤0.01% 838
2022
Q4 		$4.91M Buy
+788,366
New +$5.64M 0.02% 607
2021
Q2 		– Sell
-127,146
Closed -$3.57M – 1264
2021
Q1 		$3.57M Buy
127,146
+36,874
+41% +$1.09M 0.01% 759
2020
Q4 		$2.35M Buy
90,272
+71,877
+391% +$2.15M 0.01% 824
2020
Q3 		$684K Sell
18,395
-186
-1% -$7.37K ﹤0.01% 991
2020
Q2 		$953K Buy
18,581
+953
+5% +$39.9K ﹤0.01% 964
2020
Q1 		$556K Sell
17,628
-64,632
-79% -$3.41M ﹤0.01% 952
2019
Q4 		$4.91M Buy
+82,260
New +$3.7M 0.02% 623
2018
Q2 		– Sell
-4,700
Closed -$340K – 1363
2018
Q1 		$340K Buy
+4,700
New +$345K ﹤0.01% 1233
2015
Q4 		– Sell
-117,703
Closed -$2.78M – 1424
2015
Q3 		$2.78M Buy
117,703
+39,612
+51% +$2.49M 0.01% 707
2015
Q2 		$6.38M Hold
78,091
– – 0.03% 527
2015
Q1 		$7.23M Sell
78,091
-10,455
-12% -$675K 0.03% 478
2014
Q4 		$3.58M Buy
+88,546
New +$2.71M 0.01% 645

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Axa's ESPR Position: Q2 2023 in Review

Axa sold out of Esperion Therapeutics (ESPR) in Q2 2023, closing a stake of 782,085 shares — an estimated $1.24M sold.

Axa first reported a position in ESPR in Q4 2014 and held it in 13 quarters. The position peaked at $7.23M in Q1 2015. 124 funds tracked by Wall St. Rank hold ESPR as of Q2 2023.

  • Axa reported no remaining Esperion Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Axa sold 782,085 Esperion Therapeutics shares in Q2 2023, an estimated $1.24M.
  • Axa first reported a position in Esperion Therapeutics in Q4 2014 and held it in 13 quarters.
  • Axa's Esperion Therapeutics position peaked at $7.23M in Q1 2015.
  • 124 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2023.

Based on Axa's 13F filing for Q2 2023, filed 14 Aug 2023.